TEST:

Myriad myRisk® Hereditary Cancer

"Myriad Genetics Inc...announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventative genetic testing with a focus on high-risk populations...The collaboration combines the strengths of Myriad’s high-quality hereditary cancer and reproductive genetics products, MyRisk® with RiskScore® and Foresight® - Carrier Screen, with jscreen’s trusted education and genetic care navigation program."

"Myriad Genetics, Inc...announced a collaboration with Flatiron Health...This collaboration allows physicians to order Myriad’s MyRisk® Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR®. MyRisk is the first hereditary cancer test to be incorporated into Flatiron’s OncoEMR."

This mutation does not directly alter the catalytic region, which may explain its association with later onset disease. This case highlights the increasing availability of genetic risk information and the need for correlation to disease penetrance and phenotypes.

"Myriad Genetics, Inc...announced it will showcase 10 studies highlighting its advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 43rd Annual Conference, which will take place from Sept. 17-21, 2024, in New Orleans, LA. The research will highlight the value of genetic and genomic testing in patient care and will cover the company’s MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen and Foresight Carrier Screen....Myriad will also have a virtual presentation, Characteristics and Cancer Incidence in MITF p.E318K Carriers, available for viewing on the NSGC online experience platform. This study shows that MITF carriers have an increased risk of melanoma, but not renal cancer, as several other studies have suggested."

" Myriad Genetics, Inc...announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator."

"Myriad Genetics, Inc...and Personalis, Inc...announced a non-exclusive collaboration through which Myriad will market the Personalis®ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners who use the MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests."

"Myriad Genetics, Inc...and Onsite Women’s Health, a leading national provider of breast health services...announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk."

"Myriad Genetics, Inc...announced its MyRisk^® Hereditary Cancer Test with RiskScore^® now incorporates breast density using Tyrer-Cuzick version 8 (TCv8) to provide patients and providers with a more comprehensive look at their five-year and remaining lifetime risk for breast cancer....The Federal Drug Administration recently updated mammography regulations requiring mammography facilities to notify patients about the density of their breasts by September 2024."

"Myriad Genetics, Inc...and SimonMed Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk® with RiskScore® and patient education."

"Myriad Genetics, Inc...presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight discussion at the 2022 San Antonio Breast Cancer Symposium."

"Myriad Genetics...announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction....Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies....Additionally, there will also be poster session (P6-01-24) about an independent EndoPredict study....The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer."

"Myriad Genetics, Inc...will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn...My Risk with Risk Score, Myriad’s market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries. RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk. JCO Precision Oncology recently published a study1 that highlights the development and validation of RiskScore for women of all ancestries. The study examined data from more than 275,000 women of diverse ancestral backgrounds to validate the use of ancestry-informative genetic markers. Results showed the new method was more accurate for women of all ancestries."

"Myriad Genetics, Inc...announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care....UroSuite includes Myriad’s Prolaris® Prostate Cancer Test, MyRisk™ Hereditary Cancer Test, BRACAnalysis CDx^® and Precise™ Tumor Molecular Profile Test. The combination of tests provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection for patients....'Today’s launch of UroSuite reinforces Myriad Genetics’ commitment to advancing health and well-being for all through a set of testing solutions for prostate cancer care, best-in-class support, and access to genetics and cancer specialists,' said Paul J. Diaz, president and CEO, Myriad Genetics."